|
Carmona-Bayonas A, Alvarez-Escola C, Ballester Navarro I, Hernando Cubero J, Mangas Cruz MA, Garcia-Centeno R, Iglesias C, Garcia-Donas J, Picon MJ, Paja M, Gonzalez Batanero L, Garcia L, Alonso Gordoa T, Lopez C, Hanzu F, Martinez-Trufero J, Febrero B, Saiz-Lopez P, Blanco Carrera C, Ramon Y Cajal T, Veiguela B, Gressani O, Valdes N, Jimenez-Fonseca P. Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry. J Clin Endocrinol Metab. 2025 Oct 16;110(11):3155-3167. doi: 10.1210/clinem/dgaf082. PubMed PMID: 39988973.
AÑO: 2025; IF: 5.1
|
39988973
|
Jimenez-Fonseca P, Alvarez-Escola C, Ballester Navarro I, Hernando Cubero J, Gonzalez Fernandez L, Mangas Cruz MA, Iglesias C, Garcia-Donas J, Picon MJ, Paja M, Gonzalez Batanero L, Garcia L, Molina J, Jimeno Mate R, Aller J, Romero MDCT, Cardenas Salas J, Gutierrez-Buey G, Egana Zunzunegui N, Navarro M, Lecumberri MJ, Valdes N, Carmona-Bayonas A. External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy. Eur J Endocrinol. 2025 Jul 31;193(2):320-328. doi: 10.1093/ejendo/lvaf171. PubMed PMID: 40810251.
AÑO: 2025; IF: 5.2
|
|
Carmona-Bayonas A, Rodriguez-Gonzalez A, Garcia-Garcia T, Velasco-Durantez V, Hernandez-San Gil R, Cruz-Castellanos P, Fernandez-Montes A, Castillo-Trujillo A, Ballester I, Rogado J, Calderon C, Jimenez-Fonseca P. Can Oncologists Prompt Patient Prognostic Awareness to Enhance Decision-Making? Data From the NEOetic Study. Oncologist. 2023 Nov 2;28(11):986-995. doi: 10.1093/oncolo/oyad100. PubMed PMID: 37185783; PubMed Central PMCID: PMC10628594.
AÑO: 2023; IF: 4.8
|
|
Vicente Conesa MA, Zafra Poves M, Carmona-Bayonas A, Ballester Navarro I, de la Morena Barrio P, Ivars Rubio A, Montenegro Luis S, Garcia Garre E, Vicente V, Ayala de la Pena F. A prognostic model to identify short survival expectancy of medical oncology patients at the time of hospital discharge. ESMO Open. 2022 Feb;7(1):100384. doi: 10.1016/j.esmoop.2022.100384. Epub 2022 Feb 7. PubMed PMID: 35144121; PubMed Central PMCID: PMC8844687.
AÑO: 2022; IF: 6.883
|
|
Rosino A, Ballester I, Tudela J, González-Billalabeitia E. [Chemotherapy in metastatic castration resistant prostate cancer.]. Arch Esp Urol. 2018 Sep;71(8):676-684. Spanish. PubMed PMID: 30319127.
AÑO: 2018; IF: 0.335
|